SWX:VIFN

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Vifor Pharma AG researches, develops, produces, and markets pharmaceutical products in Switzerland, rest of Europe, the United States, and internationally. More Details


Snowflake Analysis

Flawless balance sheet with proven track record and pays a dividend.


Similar Companies

Share Price & News

How has Vifor Pharma's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: VIFN's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-8.4%

VIFN

-1.0%

CH Pharmaceuticals

-2.4%

CH Market


1 Year Return

-34.5%

VIFN

-6.0%

CH Pharmaceuticals

-4.2%

CH Market

Return vs Industry: VIFN underperformed the Swiss Pharmaceuticals industry which returned -6% over the past year.

Return vs Market: VIFN underperformed the Swiss Market which returned -4.2% over the past year.


Shareholder returns

VIFNIndustryMarket
7 Day-8.4%-1.0%-2.4%
30 Day-20.2%-8.5%-5.0%
90 Day-21.8%-5.4%-2.4%
1 Year-33.6%-34.5%-2.9%-6.0%-0.9%-4.2%
3 Year-17.8%-21.2%27.6%9.2%12.0%0.2%
5 Year-25.8%-31.0%21.7%-2.2%28.2%6.9%

Price Volatility Vs. Market

How volatile is Vifor Pharma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Vifor Pharma undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: VIFN (CHF101.7) is trading below our estimate of fair value (CHF496.65)

Significantly Below Fair Value: VIFN is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: VIFN is poor value based on its PE Ratio (40.6x) compared to the XE Pharmaceuticals industry average (21.1x).

PE vs Market: VIFN is poor value based on its PE Ratio (40.6x) compared to the Swiss market (21.4x).


Price to Earnings Growth Ratio

PEG Ratio: VIFN is poor value based on its PEG Ratio (1.9x)


Price to Book Ratio

PB vs Industry: VIFN is good value based on its PB Ratio (2x) compared to the CH Pharmaceuticals industry average (3x).


Next Steps

Future Growth

How is Vifor Pharma forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?

21.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: VIFN's forecast earnings growth (21.1% per year) is above the savings rate (-0.2%).

Earnings vs Market: VIFN's earnings (21.1% per year) are forecast to grow faster than the Swiss market (11.6% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: VIFN's revenue (11.6% per year) is forecast to grow faster than the Swiss market (4.5% per year).

High Growth Revenue: VIFN's revenue (11.6% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: VIFN's Return on Equity is forecast to be low in 3 years time (10.7%).


Next Steps

Past Performance

How has Vifor Pharma performed over the past 5 years?

-18.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: VIFN has high quality earnings.

Growing Profit Margin: VIFN's current net profit margins (8.3%) are higher than last year (5.6%).


Past Earnings Growth Analysis

Earnings Trend: VIFN's earnings have declined by 18.2% per year over the past 5 years.

Accelerating Growth: VIFN's earnings growth over the past year (61.9%) exceeds its 5-year average (-18.2% per year).

Earnings vs Industry: VIFN earnings growth over the past year (61.9%) exceeded the Pharmaceuticals industry 13.1%.


Return on Equity

High ROE: VIFN's Return on Equity (6.9%) is considered low.


Next Steps

Financial Health

How is Vifor Pharma's financial position?


Financial Position Analysis

Short Term Liabilities: VIFN's short term assets (CHF1.3B) exceed its short term liabilities (CHF548.6M).

Long Term Liabilities: VIFN's short term assets (CHF1.3B) exceed its long term liabilities (CHF678.2M).


Debt to Equity History and Analysis

Debt Level: VIFN's debt to equity ratio (15.4%) is considered satisfactory.

Reducing Debt: VIFN's debt to equity ratio has reduced from 42.7% to 15.4% over the past 5 years.

Debt Coverage: VIFN's debt is well covered by operating cash flow (88.3%).

Interest Coverage: VIFN's interest payments on its debt are well covered by EBIT (239.4x coverage).


Balance Sheet


Next Steps

Dividend

What is Vifor Pharma current dividend yield, its reliability and sustainability?

1.97%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: VIFN's dividend (1.97%) isn’t notable compared to the bottom 25% of dividend payers in the Swiss market (1.97%).

High Dividend: VIFN's dividend (1.97%) is low compared to the top 25% of dividend payers in the Swiss market (3.85%).


Stability and Growth of Payments

Stable Dividend: VIFN's dividends per share have been stable in the past 10 years.

Growing Dividend: VIFN's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: At its current payout ratio (79.8%), VIFN's payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: VIFN's dividends in 3 years are forecast to be well covered by earnings (46.5% payout ratio).


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.8yrs

Average management tenure


CEO

Stefan Schulze (55 yo)

0.42

Tenure

CHF2,353,000

Compensation

Mr. Stefan Schulze has been the Chief Executive Officer at Vifor Pharma AG since May 14, 2020 and had been its President of the Executive Committee and Chief Operating Officer at Vifor Pharma AG since May ...


CEO Compensation Analysis

Compensation vs Market: Stefan's total compensation ($USD2.59M) is about average for companies of similar size in the Swiss market ($USD2.39M).

Compensation vs Earnings: Stefan's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Stefan Schulze
Chief Executive Officer0.42yrCHF2.35m0.010%
CHF 677.8k
Colin Bond
Chief Financial Officer3.42yrsno data0.0057%
CHF 374.9k
Alex Sigalas
Head of Finance4.75yrsno datano data
Julien Vignot
Head of Investor Relations & Treasuryno datano datano data
Oliver Kronenberg
Group General Counsel6.75yrsno datano data
Nathalie Ponnier
Global Head Corporate Communicationsno datano datano data
Michael Puri
Chief Human Resources Officer5.42yrsno data0.0045%
CHF 295.0k
Christoph Springer
Chief Strategy Officer4.75yrsno data0.037%
CHF 2.5m
Thomas Kaspar
Head of Global Quality Management9.75yrsno datano data
Thierry Teil
Head of Global Medical Affairs4.75yrsno datano data
Carolina Ponchione
Head of Executive Search & Employer Branding2.75yrsno datano data
Barbara Angehrn
Chief Business Officer1.92yrsno data0.00013%
CHF 8.6k

4.8yrs

Average Tenure

52yo

Average Age

Experienced Management: VIFN's management team is considered experienced (4.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Jacques Theurillat
Independent Chairman of the Board0.42yrCHF195.00k0.00086%
CHF 56.8k
Gilbert Achermann
Director0.42yrno datano data
Etienne Jornod
Honorary Chairman0.42yrCHF4.50m0.44%
CHF 29.2m
Gianni Zampieri
Director3.42yrsCHF173.00k0.076%
CHF 5.0m
Michel Burnier
Independent Director10.75yrsCHF192.00k0.013%
CHF 876.4k
Romeo Cerutti
Independent Deputy Chairman & Lead Independent Director1.75yrsCHF238.00k0.0084%
CHF 555.0k
Kim Stratton
Independent Director1.42yrsCHF123.00kno data
Susan Mahony
Independent Director1.42yrsCHF145.00kno data

1.4yrs

Average Tenure

59.5yo

Average Age

Experienced Board: VIFN's board of directors are not considered experienced ( 1.4 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Vifor Pharma AG's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Vifor Pharma AG
  • Ticker: VIFN
  • Exchange: SWX
  • Founded: 1872
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CHF6.600b
  • Shares outstanding: 64.89m
  • Website: https://www.viforpharma.com

Number of Employees


Location

  • Vifor Pharma AG
  • Rechenstrasse 37
  • Sankt Gallen
  • St. Gallen
  • 9014
  • Switzerland

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
VIFNSWX (SIX Swiss Exchange)YesRegistered SharesCHCHFFeb 2003
G2AADB (Deutsche Boerse AG)YesRegistered SharesDEEURFeb 2003
GNHA.FOTCPK (Pink Sheets LLC)YesRegistered SharesUSUSDFeb 2003
0RPDLSE (London Stock Exchange)YesRegistered SharesGBCHFFeb 2003
GNHA.YOTCPK (Pink Sheets LLC)UNSPONSERED ADRUSUSDApr 2012
G2ABDB (Deutsche Boerse AG)UNSPONSERED ADRDEEURApr 2012

Biography

Vifor Pharma AG researches, develops, produces, and markets pharmaceutical products in Switzerland, rest of Europe, the United States, and internationally. The company offers Ferinject/Injectafer, a soluti ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/28 21:55
End of Day Share Price2020/10/28 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.